Literature DB >> 12663983

Brachiobasilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-related complications.

Ahmed Hossny1.   

Abstract

OBJECTIVE: Easy access to the vascular system is vital in patients with chronic renal failure undergoing long-term hemodialysis. Such patients often require multiple operations, and options for secondary or tertiary access procedures become increasingly limited. Brachiobasilic arteriovenous fistula offers excellent access in such difficult cases and is increasingly preferred over prosthetic grafts. Many surgical techniques have been described to create such fistulas. The purpose of this study was to determine the difference in long-term patency and dialysis-related complications among various techniques.
METHODS: Seventy brachiobasilic arteriovenous fistulas were constructed in 70 patients. This was the secondary or tertiary access in 88.6% of patients. The basilic vein was transposed in 30 patients and elevated in 40 patients; twenty veins were elevated with a one-stage technique, and 20 were elevated with a two-stage (delayed elevation) technique.
RESULTS: The early failure rate was 5.7% in the entire group. Sixty-six fistulas (94.3%) were successfully used for dialysis. Mean follow-up was 25.8 months (range, 4-36 months). Four fistulas (5.7%) required additional procedures during follow-up, 2 in the transposed vein group and 2 in the elevated vein group. Cumulative secondary patency rate, measured with the Kaplan-Meier survival method, was 86.7%, 90%, and 84.2% at 1 year for the transposed, one-stage, and two-stage elevation procedures, respectively, compared with 82.8%, 70%, and 68.4% at 2 years. The difference was statistically nonsignificant. Forty-two complications developed in 29 (43.9%) fistulas. Thirteen fistulas (19.7%) had more than one complication. Twelve complications in 10 fistulas (35.7%) were recorded in the transposition group, 15 complications in 9 fistulas (47.4%) in the one-stage elevation group, and 15 complications in 10 fistulas (52.6%) in the two-stage elevation group. The total complication rate was higher in the elevated fistulas (71.4% vs 28.6%); the difference was statistically highly significant (P <.001). The most common complication was arm edema (21.2%; n = 14), followed by puncture site-related hematoma (16.7%; n = 11) and thrombosis (16.7%; n = 11). Hematoma was statistically more common (P <.05) in the elevated vein group (26.3% vs 3.6%). The difference in thrombosis between the transposition and elevation groups (23.7% vs 7.1%) was not significant. Hematoma preceded thrombosis in 63.7% (7 of 11) of the fistulas, and it was the major predisposing factor for fistula failure. Transposed vein was easier to manage by dialysis staff. All nurses were satisfied with the transposed veins, but only 53.3% were satisfied with the elevated veins; the difference was statistically highly significant (P <.001).
CONCLUSION: Available techniques for creating brachiobasilic arteriovenous fistula are associated with good patency rate, and most related complications can be treated conservatively without loss of the fistula. Among the various procedures, transposition has a lower complication rate and is favored by the dialysis staff dealing with such fistulas.

Entities:  

Mesh:

Year:  2003        PMID: 12663983     DOI: 10.1067/mva.2003.181

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  20 in total

1.  Fistula first: recent progress and ongoing challenges.

Authors:  Michael Allon
Journal:  Am J Kidney Dis       Date:  2011-01       Impact factor: 8.860

2.  Selective two-stage basilic and cephalic vein transpositions can significantly improve the rate of fistula construction.

Authors:  Homayoun Hashemi; Michael J Sheridan; Beverly Ford
Journal:  Int J Angiol       Date:  2009

3.  Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study.

Authors:  Alik Farber; Peter B Imrey; Thomas S Huber; James M Kaufman; Larry W Kraiss; Brett Larive; Liang Li; Harold I Feldman
Journal:  J Vasc Surg       Date:  2016-01       Impact factor: 4.268

4.  Transposition of brachiobasilic arteriovenous fistulae: improving the cosmetic effect without compromising patency.

Authors:  David van Dellen; Muneer Junejo; Hussein Khambalia; Babatunde Campbell
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

5.  Basilic Vein Elevation for Arteriovenous Fistula Creation: Results of 60 Cases Following 1 Year.

Authors:  Grigol Keshelava; Kote Gvalia; Davit Kovziridze; Marina Dadunashvili; Vakhtang Kaloiani
Journal:  Int J Angiol       Date:  2015-12-04

6.  Early and midterm patency of arteriovenous fistula for hemodialysis access using different techniques and their advantages and disadvantages.

Authors:  Vikas Deep Goyal; Akhilesh Pahare; Shobhit Sharma; Gaurav Misra
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-08-08

7.  Hemodialysis vascular access options after failed Brescia-Cimino arteriovenous fistula.

Authors:  Aneesh Srivastava; Sandeep Sharma
Journal:  Indian J Urol       Date:  2011-04

8.  Randomized controlled trial comparing primary and staged basilic vein transposition.

Authors:  Stavros K Kakkos; Ioannis A Tsolakis; Spyros I Papadoulas; George C Lampropoulos; Evangelos E Papachristou; Nikolaos C Christeas; Dimitrios Goumenos; Miltos K Lazarides
Journal:  Front Surg       Date:  2015-04-29

9.  Native arterio-venous fistula is the vascular access of choice for hemodialysis in end stage renal disease.

Authors:  Farooq Ahmad Ganie; Hafeezulla Lone; Abdul Majeed Dar; Ghulam Nabi Lone; Mohd Lateef Wani
Journal:  Int Cardiovasc Res J       Date:  2013-06-01

10.  Comparison of one- and two-stage basilic vein transposition for arterio-venous fistula formation in haemodialysis patients: preliminary results.

Authors:  Sedat Ozcan; Ali Kemal Gür; Ali Umit Yener; Dolunay Odabaşi
Journal:  Cardiovasc J Afr       Date:  2013 Oct-Nov       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.